Clinical Scorecard: Investigating the Influence of Apelin and Ghrelin in Multiple Sclerosis: A Study of Patients Undergoing Immunomodulatory Treatment

At a Glance

Key Highlights

• Natalizumab-treated patients showed higher apelin levels compared to controls, indicating potential metabolic implications.
• Fingolimod-treated patients exhibited significantly higher ghrelin levels than controls, with gender differences noted.
• Ghrelin levels in women with MS increased with disease duration, suggesting a need for gender-specific monitoring.
• Apelin levels correlated positively with BMI in the fingolimod-treated group, highlighting metabolic health considerations.
• Study suggests a link between immunomodulatory treatment and peptide hormone regulation, warranting further investigation.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

• Monitor changes in apelin and ghrelin levels during treatment, ideally every 3-6 months.

Risks

Patient & Prescribing Data

Differences in hormone levels may influence treatment outcomes and metabolic health, suggesting tailored approaches.

Clinical Best Practices

• Assess metabolic factors in MS patients undergoing immunomodulatory treatment, considering hormone levels in treatment plans.
• Incorporate hormone level monitoring into routine care for MS patients, adjusting treatment based on findings.

References

• Investigating the Influence of Apelin and Ghrelin in Multiple Sclerosis